利拉鲁肽联合阿法骨化醇治疗老年2型糖尿病合并骨质疏松的疗效分析

Efficacy analysis of Liraglutide Combined with Alfacalcidol in the Treatment of Elderly Type 2 Diabetes Mellitus Complicated with Osteoporosis

目的 研究利拉鲁肽联合阿法骨化醇治疗老年2型糖尿病合并骨质疏松的临床疗效以及治疗指标的改善效果。方法 选择该院2018年1月—2021年1月期间收治的60例老年2型糖尿病合并骨质疏松患者作为研究对象,按照随机数字表法分成对照组和观察组,各30例,通过单纯阿法骨化醇治疗的患者为对照组,通过利拉鲁肽联合阿法骨化醇治疗的患者为观察组,比较两组患者的临床治疗总有效率、空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、体质指数(BMI)、治疗前后的胰岛功能指标水平(HOMA-β、HOMAIR)、不良反应发生率(恶心、胃部不适)。结果 观察组患者的临床治疗总有效率(96.7%)高于对照组(70.0%),差异有统计学意义(χ^(2)=7.680,P<0.05);观察组患者的FPG、2 hPG、HbA1c、BMI均优于对照组患者,差异有统计学意义(P<0.05);观察组患者的不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。治疗前,两组患者的胰岛功能指标水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者的HOMA-IR低于对照组患者,观察组患者的HOMA-β高于对照组患者,差异有统计学意义(P<0.05)。结论 老年2型糖尿病合并骨质疏松患者通过利拉鲁肽联合阿法骨化醇治疗,可以有效提升临床疗效,改善治疗指标,安全性较高,值得推广。

Objective To study the clinical efficacy of liraglutide combined with alfacalcidol in the treatment of elderly patients with type 2 diabetes mellitus complicated with osteoporosis and the improvement effect of therapeutic indicators.Methods Selected 60 elderly patients with type 2 diabetes and osteoporosis who were admitted to the hospital from January 2018 to January 2021 as the subjects,and they were divided into control group and observation group according to the random number table method,with 30 cases in each group.The patients treated with alfacalcidol alone were the control group,and the patients treated with liraglutide combined with alfacalcidol were the observation group.The total effective rate of clinical treatment,fasting blood glucose(FPG),2 h postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),body mass index(BMI),and pancreatic islet function index(HOMA-β,HOMA-IR) before and after treatment were compared between the two groups,incidence of adverse reactions(nausea,upset stomach).Results The total effective rate of clinical treatment in the observation group(96.7%)was higher than that in the control group(70.0%),and the difference was statistically significant(χ^(2)=7.680,P<0.05).The FPG,2 h PG,Hb A1c and BMI of the observation group were better than those of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Before treatment,there was no statistically significant difference in the levels of pancreatic islet function indexes between the two groups(P>0.05).After treatment,the HOMA-IR of the observation group was lower than that of the control group,and the HOMA-β of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Liraglutide combined with alfacalcidol can effectively improve the clinical efficacy and improve the therapeutic indicators in elderly patients with type 2 diabetes and osteoporosis,with high safety and worthy of promotion.